Effect of nebulized magnesium sulphate in acute bronchiolitis

Phase 3

• Conditions: Health Condition 1: null- Acute BronchiolitisHealth Condition 2: J219- Acute bronchiolitis, unspecified

• Registration Number: CTRI/2017/02/007919
• Lead Sponsor: Dept Of paediatrics GMSH Chandigarh

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 104

Inclusion Criteria

Children of 2-12 months old with diagnosis of acute bronchiolitis with short history of cough with or without fever of less than 7 days duration and wheezing on examination and with first attack of wheezing.

Exclusion Criteria

Patient with past history of wheeze,family history of bronchial asthma, presence of congenital heart disease or congenital malformation,history of prematurity or mechanical ventilation in newborn period, pneumonia or pleural effusion, SAM, very sick patient with shock, seizures, tachycardia (HR >200/min) and respiratory failure, foreign body ingestion, history of nebulization of any drug in past.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in Respiratory Distress Assessment (RDAI) scoreTimepoint: RDAI score shall be assessed at admission,at 3,6,12,18,24,36,48,60,72,84,96 hours and at discharge.

Secondary Outcome Measures

Name	Time	Method
Duration of hospital stayTimepoint: At discharge;Improvement in Spo2Timepoint: Improvement in spo2 is assessed at admission, at 3,6,12,18,24,36,48,60,72,84,96hrs and at discharge.